Platform
Home
Screener
Copilot
AskEdgar Studio
New
Back
Altimmune, Inc.
ALT ยท SEC Filings
website
57
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for o...
Price
2.12
Market Cap
435.28 M
Float
204.95 M
Country
US
Sector
Healthcare
Exchange
NASDAQ
Overview
Filings
Insights
Dilution
News
Transcripts
Search in Documents
Open in Studio
Studio
Login
Ask about ALT
TYPE
HEADLINE
FILED AT
TYPE
HEADLINE
FILED AT
TYPE
HEADLINE
FILED AT
TYPE
HEADLINE
FILED AT
All
Chronological
Financials
Registrations
Prospectus
News
Proxies
Ownerships
Other
Altimmune, Inc.
ALT ยท SEC Filings
204.95 M
Float
2.12
Price
435.28 M
Market Cap
Financials
TYPE
HEADLINE
FILED AT
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Aug 12, 2026
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
May 13, 2026
10-K
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Mar 6, 2026
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Nov 6, 2025
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Aug 12, 2025
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
May 13, 2025
News
TYPE
HEADLINE
FILED AT
8-K
Altimmune Draws $10.0 Million Under Loan Agreement and Extends Interest-Only Period
Oct 29, 2026
8-K
Altimmune Appoints Peter Greenleaf and Alex Howarth to Board of Directors
Oct 27, 2026
8-K
Altimmune Appoints Richard Menziuso as Vice President, Global Controller and Principal Accounting Officer
Sep 29, 2026
8-K
Altimmune Announces Second Quarter 2026 Financial Results and Business Update
Aug 12, 2026
8-K
Altimmune Announces Positive Topline Results from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder
Jul 28, 2026
8-K
Altimmune, Inc. Announces Corporate Headquarters Relocation to New Jersey
Jun 16, 2026
Prospectus
TYPE
HEADLINE
FILED AT
424B5
REGISTERED OFFERING
Apr 23, 2026
424B5
PENDING FIXED PRICE OFFERING | Bank: Leerink Partners, Barclays, Titan Partners
Apr 22, 2026
424B5
REGISTERED OFFERING
Jan 28, 2026
424B5
November 2025 ATM
Nov 6, 2025
424B5
310,839 shares reserved for issuance under our 2019 Employee Stock Purchase Plan; and-
Feb 25, 2021
424B5
3,369,564 Shares of Common Stock
Jul 14, 2020
Registrations
TYPE
HEADLINE
FILED AT
S-8
Form S-8 - Securities to be offered to employees in employee benefit plans
May 13, 2026
S-3MEF
April 2026 SHELF
Apr 22, 2026
S-8
Form S-8 - Securities to be offered to employees in employee benefit plans
Feb 6, 2026
S-3/A
November 2025 SHELF
Nov 13, 2025
S-3
November 2025 SHELF
Nov 6, 2025
S-3
Form S-3 - Registration statement under Securities Act of 1933
Feb 27, 2025
Proxies
TYPE
HEADLINE
FILED AT
DEF 14A
Form DEF 14A - Other definitive proxy statements
Mar 17, 2026
PRE 14A
Form PRE 14A - Other preliminary proxy statements
Mar 6, 2026
DEF 14A
Form DEF 14A - Other definitive proxy statements
Aug 15, 2025
DEF 14A
Form DEF 14A - Other definitive proxy statements
Aug 15, 2024
DEF 14A
Form DEF 14A - Other definitive proxy statements
Aug 16, 2023
DEF 14A
Form DEF 14A - Other definitive proxy statements
Aug 16, 2022
Ownerships
TYPE
HEADLINE
FILED AT
4
Greenleaf Peter (Reporting)
Nov 4, 2026
3
Greenleaf Peter (Reporting)
Nov 4, 2026
4
Howarth Alex G. (Reporting)
Nov 4, 2026
3
Howarth Alex G. (Reporting)
Nov 4, 2026
4
Arbet-Engels Christophe (Reporting)
Oct 5, 2026
4
WEAVER GREGORY L (Reporting)
Oct 5, 2026
Chronological
TYPE
HEADLINE
FILED AT
Other
TYPE
HEADLINE
FILED AT
EFFECT
Form EFFECT - Notice of Effectiveness
Dec 8, 2025
CORRESP
Form CORRESP - Correspondence
Dec 3, 2025
LETTER
Form UPLOAD - SEC-generated letter
Aug 19, 2025
CORRESP
Form CORRESP - Correspondence
Aug 12, 2025
LETTER
Form UPLOAD - SEC-generated letter
Aug 8, 2025
EFFECT
Form EFFECT - Notice of Effectiveness
Mar 14, 2025
